Summit Therapeutics Inc. (SMMT) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Cambridge, MA, United States. वर्तमान CEO हैं Robert W. Duggan.
SMMT के पास है IPO तिथि 2015-03-05, 159 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Market, बाजार पूंजीकरण $15.72B.
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to treat infectious diseases in the United States and Latin America. The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic currently in Phase III clinical trials for Clostridioides difficile infection (CDI). Summit's pipeline also includes SMT-738, designed to address multidrug-resistant infections such as carbapenem-resistant Enterobacteriaceae, and the DDS-04 series for treating Enterobacteriaceae infections. Founded in 2003 and headquartered in Cambridge, Massachusetts, the company is advancing its clinical programs to address critical unmet needs in infectious disease treatment.
